PMSF

SKU: orb1310290

Description

PMSF (Phenylmethylsulfonyl fluoride) is an irreversible serine/cysteine protease inhibitor commonly used to prevent protein degradation during cell lysis. It is a staple reagent in biochemistry and cell biology for both in vitro enzymatic assays and the preparation of protein extracts from tissues or cultured cells.

Research Area

Protein Biochemistry

Key Properties

• CAS Number: 329-98-6
• MW: 174.19
• Purity: 97.75% (May vary between batches)
• Formula: C₇H₇FO₂S
• SMILES: FS(=O)(=O)Cc1ccccc1
• Target: Cysteine Protease,Serine Protease
• Solubility: Ethanol:17.4 mg/mL (99.89 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (28.7 mM);DMSO:257.5 mg/mL (1478.27 mM)

Bioactivity

• Target IC50:
  Remain immobile (mouse):206 mg/kg (ED50)|antinociception (mouse):86 mg/kg (ED50)|hypothermia (mouse):224 mg/kg (ED50)|Neutrophil:95 μM|Neutrophil:130.9 μM|Neutrophil:22.8 μg/mL
• In Vivo:
  METHODS: To study the analgesic effect of PMSF, PMSF was intraperitoneally injected into mice. RESULTS: Mice exhibited cannabinoid effects: including analgesia, hypothermia and immobility, with ED50 values of 86, 224 and 206 mg/kg, respectively.
• In Vitro:
  Treatment with PMSF (intraperitoneal injection) in mice elicits cannabinoid-like effects, providing analgesia (ED50: 86 mg/kg), hypothermia (ED50: 224 mg/kg), and catalepsy (ED50: 206 mg/kg). When administered to Sprague-Dawley rats, PMSF induces a dose-dependent analgesic effect and significantly potentiates the analgesic effect of β-endorphin in vivo. By inhibiting fatty acid amide hydrolase (FAAH) activity, PMSF suppresses typical cannabinoid or Δ(9)-tetrahydrocannabinol-like effects in ICR mice. Pretreatment with 30 mg/kg PMSF before the injection of [3H]-labeled cannabinoids results in a notable increase in brain cannabinoid levels after 5 minutes compared to [3H]-THC. PMSF pretreatment at 30 mg/kg enhances the cannabinoid-induced effects on the tail-flick response (analgesic effect), locomotion, and spontaneous activity by 5, 8, and 10-fold respectively. Administering PMSF 12 hours before paraoxon (PSP) protects hens from delayed neurotoxicity, whereas administration 4 hours later exacerbates the neurotoxic effects. PMSF pretreatment also prevents organophosphate-induced delayed neuropathy in hens and inhibits neuropathilament degeneration induced by tri-ortho-tolyl phosphate.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Cysteine protease, Cysteine Protease, CysteineProtease, Benzylsulfonyl Fluoride, Benzylsulfonyl fluoride, Cathepsin, inhibit, PMSF, Inhibitor, Phenylmethylsulfonyl fluoride, Phenylmethylsulfonyl Fluoride, Serine Protease, SerineProtease

Compound Identifiers

PubChem CID

4784